Today Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Reported Increase in Shorted Shares

June 16, 2018 - By Peter Erickson

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Logo

The stock of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) registered an increase of 2.13% in short interest. ZYNE’s total short interest was 2.74M shares in June as published by FINRA. Its up 2.13% from 2.68M shares, reported previously. With 256,500 shares average volume, it will take short sellers 11 days to cover their ZYNE’s short positions. The short interest to Zynerba Pharmaceuticals Inc’s float is 25.38%.

The stock decreased 1.74% or $0.2 during the last trading session, reaching $11.3. About 200,481 shares traded. Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has declined 46.38% since June 16, 2017 and is downtrending. It has underperformed by 58.95% the S&P500.

Zynerba Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. The company has market cap of $153.24 million. The Company’s product candidates include ZYN002, which is in Phase II clinical trial for adult patients with refractory epileptic focal seizures and osteoarthritis, as well as pediatric patients with fragile X syndrome; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. It currently has negative earnings. The firm was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014.

More news for Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) were recently published by:, which released: “Medical Cannabis Market Projects Growth Across North America” on May 31, 2018.‘s article titled: “International Cannabis Legalization to Spur Global Medical and Recreational Sales” and published on June 13, 2018 is yet another important article.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: